

# Claudia Giordano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9069026/publications.pdf>

Version: 2024-02-01

17  
papers

130  
citations

1478505

6  
h-index

1281871

11  
g-index

17  
all docs

17  
docs citations

17  
times ranked

182  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of COVID-19 pandemic on 2-[18F]FDG PET/CT imaging work-flow in a single medical institution: comparison among the three Italian waves. <i>Heliyon</i> , 2022, 8, e08819.	3.2	6
2	Sulfur Hexafluoride Contrast-Enhanced Ultrasound Showing Early Wash-Out of Marked Degree Identifies Lymphoma Invasion of Spleen with Excellent Diagnostic Accuracy: A Monocentric Study of 260 Splenic Nodules. <i>Cancers</i> , 2022, 14, 1927.	3.7	3
3	Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study. <i>British Journal of Haematology</i> , 2022, 198, 847-860.	2.5	9
4	Correspondence in reference to previously published manuscript: "Faouzi Djebbari et al. Efficacy and infection morbidity of front-line immunochemotherapy in follicular lymphoma. <i>Eur J Haematol</i> . 2020; 105: 667-671"; European Journal of Haematology, 2021, 106, 734-736.	2.2	2
5	Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 158, 103203.	4.4	4
6	Regarding "Hepatitis B Surface Antigen Positivity is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era". <i>Oncologist</i> , 2021, 26, e1083-e1084.	3.7	1
7	Correspondence in reference to the previously published Epub manuscript: "Murt Ahmet et al. Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country. <i>Annals of Hematology</i> 2020; 99: 2671-2677"; <i>Annals of Hematology</i> , 2021, 100, 1631-1633.	1.8	1
8	Correspondence in reference to the previously published Epub manuscript by Peter Hokland et al. "How I treat advanced Hodgkin lymphoma: a global view". <i>Br J Haematol</i> . 2020;190:837-845. <i>British Journal of Haematology</i> , 2021, 193, e5-e8.	5.0	2
9	Comment on "Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study". <i>Haematologica</i> , 2021, 106, 1226-1227.	3.5	0
10	Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up. <i>Cancers</i> , 2021, 13, 1760.	3.7	7
11	Long-term Cryopreserved Autologous Hematopoietic Stem Cells Following Azacytidine to Successfully Treat Severe Invasive Pulmonary Aspergillosis After Therapy-Related Myelodysplastic Syndrome and CD8+ T-cell Autoimmune Disorders: A Case Report. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e722-e725.	0.4	1
12	Hashimoto Thyroiditis in Primary Thyroid Non-Hodgkin Lymphoma. <i>American Journal of Clinical Pathology</i> , 2020, 153, 156-164.	0.7	30
13	Sjögren Syndrome in Primary Salivary Gland Lymphoma. <i>American Journal of Clinical Pathology</i> , 2020, 153, 719-724.	0.7	14
14	Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis. <i>Cancer Medicine</i> , 2019, 8, 2802-2809.	2.8	7
15	Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma. <i>Blood Advances</i> , 2019, 3, 1546-1552.	5.2	23
16	Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL. <i>Blood</i> , 2019, 133, 498-501.	1.4	16
17	Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2018, 182, 715-718.	2.5	4